Search results for "gastric"

showing 10 items of 536 documents

A106 Gastroesophageal reflux disease in patients with severe obesity and type 2 diabetes one year after sleeve gastrectomy or Roux-en-Y gastric bypas…

2019

Sleeve gastrectomymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGastric bypassRefluxType 2 diabetesDiseasemedicine.diseaseRoux-en-Y anastomosislaw.inventionSurgeryRandomized controlled triallawMedicineSurgeryIn patientbusinessSurgery for Obesity and Related Diseases
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

Modified Devine Exclusion for Unresectable Distal Gastric Cancer in Symptomatic Patients

2017

<b><i>Background:</i></b> In patients with outlet obstruction syndrome and/or severe anemia secondary to unresectable gastric cancer (GC), partial stomach-partitioning gastrojejunostomy, or modified Devine exclusion, is a surgical alternative. <b><i>Methods:</i></b> A retrospective study was conducted on patients with unresectable distal GC treated with modified Devine exclusion as palliative surgery between February 2005 and December 2015. It consisted of a series of 10 patients with outlet obstruction syndrome and/or severe anemia. The outcomes of this technique were based on oral tolerance, blood transfusions, postoperative complications, a…

Stomach neoplasmmedicine.medical_specialtyPalliative caremedicine.medical_treatment030230 surgeryGastroenterologyPalliative surgery03 medical and health sciences0302 clinical medicineInternal medicinemedicineCase Serieslcsh:RC799-869Oral tolerancebusiness.industryGastroenterologyCancerGastric outlet obstructionRetrospective cohort studyStomach neoplasmGastroenterostomymedicine.disease030220 oncology & carcinogenesisGastric outlet obstructionPalliative carelcsh:Diseases of the digestive system. GastroenterologybusinessGastroenterostomyCase Reports in Gastroenterology
researchProduct

Porcine Model for Deep Superior Epigastric Artery Perforator Flap Harvesting: Anatomy and Technique

2018

BACKGROUND Microsurgical training on rats before starting with clinical practice is a well-established routine. Animal model training is less widespread for perforator flaps, although these flaps represent a technical challenge. Unlike other flaps, they require specific technical skills that need to be adequately trained on a living model 1 : a cadaver is not enough because no bleeding, vessel damage, or vasospasm can be simulated. 2 The purpose of this study was to assess the suitability of the porcine abdomen as a training model for the deep inferior epigastric artery perforator (DIEAP) flap, commonly used in human breast reconstruction. METHODS A female swine (Sus scrofa domesticus, ssp;…

Superior epigastric arteryMicrosurgical training DIEP breast reconstruction free flap living animal modelbusiness.industrylcsh:SurgeryAnatomylcsh:RD1-811030230 surgery03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicine.arteryMedicineSurgerybusinessporcine model Deep Superior Epigastric Artery Perforator FlapSICPRE AbstractsPlastic and Reconstructive Surgery Global Open
researchProduct

Laparoscopic Epigastric Hernia Repair

2016

Epigastric hernias are midline abdominal wall defects located between the umbilicus and the xiphoid process that do not resolve spontaneously. Symptomatic hernias require surgical repair.

Surgical repairmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryUmbilicus (mollusc)Epigastric herniamedicine.diseaseXiphoid processdigestive system diseasesSurgerybody regionsAbdominal wallstomatognathic diseasessurgical procedures operativemedicine.anatomical_structuremedicineLinea alba (abdomen)HerniabusinessLaparoscopy
researchProduct

The “RENAISSANCE” Trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients wit…

2017

TPS4140 Background: Recent data indicates that surgical resection may bring a benefit for select patients with metastatic gastric / esophagogastric junction cancer. However, no data obtained in randomized trials is available up to now. The current RENAISSANCE trial investigates this long-lasting question about the role of surgical intervention in limited-metastatic gastric / esophagogastric junction cancer. Methods: This is a prospective, multicenter, randomized, investigator initiated phase III trial. In this study, previously untreated patients with limited metastatic stage (retroperitoneal lymph node metastases only or a maximum of one incurable organ site that is potentially resectable…

Surgical resectionCancer Researchmedicine.medical_specialtyChemotherapybusiness.industryStomachmedicine.medical_treatmentThe RenaissanceCancermedicine.diseaseSurgery03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOncologyQuality of life030220 oncology & carcinogenesisMedicineIn patientEsophagogastric junctionbusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Splenic lymphoma with complex gastro-spleno-diaphragmatic fistula: 3D laparoscopic multivisceral resection. The first literature case report

2020

Abstract Introduction Gastrosplenic fistula is a rare disease involving stomach and spleen that can lead to dangerous complications like massive gastrointestinal bleeding. Diffuse large B-cell lymphoma (DLBC) is the principal pathological cause of gastrosplenic fistula. Case report We report a case of A 76-year-old caucasian woman came to the emergency room with fever for two week and gravative pain in left upper quadrant of the abdomen. CT scan of thorax and abdomen demonstrated an inhomogeneous hypodense large lymphomatous mass (10 × 6 cm) of upper pole of the spleen deformating medial profile and infiltrating gastric fundus and left diaphragm. with the diagnosis of complex gastro-splenic…

Thoraxmedicine.medical_specialtyGastrointestinal bleedingFistulaSplenic lymphomaCase Report03 medical and health sciences0302 clinical medicinemedicine3D laparoscopic surgeryLaparoscopymedicine.diagnostic_testbusiness.industryGastric lymphomamedicine.diseasemedicine.anatomical_structure030220 oncology & carcinogenesisMultivisceral resectionAbdomen030211 gastroenterology & hepatologySurgeryRadiologyGastric fistulaSplenic LymphomabusinessRare diseaseInternational Journal of Surgery Case Reports
researchProduct

T-bet and mucosal Th1 responses in the gastrointestinal tract

2002

T cells play an essential role in regulating mucosal immune responses in the gastrointestinal tract. Recent observations on T helper cell differentiation and activation by regulatory transcription factors-especially T-bet-in chronic inflammatory diseases have provided new perspectives for understanding mucosal immunity. Here we summarise recent advances in the field of transcription factors and discuss the implications of these findings for future therapeutic approaches in inflammatory bowel diseases. In particular, we have focused on the role of T-bet in controlling mucosal Th1 responses in the gastrointestinal tract.

Transcription GeneticCellular differentiationGene Expressionchemical and pharmacologic phenomenaInflammationLeading ArticleBiologyInterferon-gammaMiceImmune systemImmunopathologymedicineAnimalsHumansT-helper cell differentiationImmunity MucosalTranscription factorImmunity CellularGastrointestinal tractT-cell receptorGastroenterologyCell DifferentiationTh1 CellsInflammatory Bowel DiseasesGastric MucosaImmunologyCytokinesmedicine.symptomT-Box Domain ProteinsDigestive SystemInterleukin-1Transcription FactorsGut
researchProduct

1432P Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced g…

2021

TranscriptomeImmune systemOncologybusiness.industrymedia_common.quotation_subjectMedicineHematologyComputational biologyAdvanced gastric cancerGene signaturebusinessDiversity (politics)media_commonAnnals of Oncology
researchProduct

Mecanismos de resistencia primaria y secundaria a tratamiento anti HER2 en cancer gástrico HER2 positivo

2018

El cáncer gástrico (CG) cuando se diagnostica en estadio avanzado debe considerarse una enfermedad incurable, con una mediana de supervivencia global (OS) de 12 meses. La identificación de las características moleculares de CG ha llevado al descubrimiento de rutas intracelulares y genes que contribuyen a la carcinogénesis (1). Entre estas alteraciones, la amplificación de HER2, detectable en 7-14% de los casos (2), juega un papel clave en el crecimiento celular, en la supervivencia y en la diferenciación celular (3-4). Un ensayo fase III, demostró el beneficio derivado de añadir trastuzumab, anticuerpo monoclonal que se une de manera selectiva y eficiente al receptor HER2, a quimioterapia b…

UNESCO::CIENCIAS MÉDICASCancer gastrico:CIENCIAS MÉDICAS [UNESCO]mecanismos de resistencia
researchProduct